Summary
Abbott Laboratories (ABT) filed an 8-K on April 20, 2021, to report its first-quarter 2021 financial results. The filing primarily serves to furnish a press release detailing these results. Investors should note that Abbott utilizes non-GAAP financial measures, such as net earnings excluding specified items, to provide a clearer view of ongoing operational performance by excluding unusual or unpredictable expenses like acquisition-related costs, restructuring, and litigation. While these non-GAAP measures are presented to offer additional insights and are used internally by management, they should be considered alongside GAAP measures. The press release, incorporated by reference, contains the detailed financial performance for the quarter. Investors are encouraged to review this document for specific figures regarding revenue, earnings, and segment performance. The use of non-GAAP measures is a common practice to highlight core business trends, but it's crucial for investors to understand the adjustments made and to assess the company's performance holistically.
Key Highlights
- 1Abbott Laboratories announced its first-quarter 2021 financial results on April 20, 2021, via an 8-K filing.
- 2The 8-K filing includes a press release with the detailed Q1 2021 financial results, incorporated by reference.
- 3Abbott utilizes non-GAAP financial measures, such as net earnings excluding specified items, in its earnings announcements.
- 4These non-GAAP measures adjust for unusual or unpredictable items, including acquisition expenses, restructuring, litigation, and tax benefits.
- 5The company states these non-GAAP measures provide greater visibility into ongoing business performance and are used internally by management.
- 6Investors are cautioned to consider these non-GAAP measures in addition to, and not as a substitute for, GAAP financial measures.
- 7The filing also includes an interactive data file for the cover page.